28 Mar 2025 • A post-hoc analysis evaluating a Liraglutide biosimilar in Indian T2DM patients with obesity found that the biosimilar was non-inferior to the reference liraglutide in both weight reduction and glycemic control.

Among the patients (BMI >25 kg/m²), those receiving the biosimilar achieved a mean weight loss of 5.5 ± 1.2 kg, while the reference liraglutide group lost 7.1 ± 2.6 kg, with no significant difference at 24 weeks.

HbA1c, fasting plasma glucose (FPG), and postprandial glucose (PPG) improved significantly in both groups, with no meaningful differences between them.

Source: BMC | Read Full Story